These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 19224452)
21. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors]. Lang A; Graeven U Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236 [No Abstract] [Full Text] [Related]
22. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. Höpfner M; Schuppan D; Scherübl H World J Gastroenterol; 2008 Jan; 14(1):1-14. PubMed ID: 18176955 [TBL] [Abstract][Full Text] [Related]
23. Targeted therapy in esophageal cancer. Zhang L; Ma J; Han Y; Liu J; Zhou W; Hong L; Fan D Expert Rev Gastroenterol Hepatol; 2016; 10(5):595-604. PubMed ID: 26895097 [TBL] [Abstract][Full Text] [Related]
24. Targeting novel and established therapies for non-small cell lung cancer. Spicer J; Chowdhury S; Harper P Cancer Lett; 2007 May; 250(1):9-16. PubMed ID: 17030089 [TBL] [Abstract][Full Text] [Related]
25. [Molecular structure and abnormal expression of angiopoietin-2 and antiangiogenic targeting therapy of hepatocelluar carcinoma]. GU WJ; YAO DF Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):398-400. PubMed ID: 19497214 [No Abstract] [Full Text] [Related]
26. Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Chua W; Moore MM; Charles KA; Clarke SJ Curr Opin Mol Ther; 2009 Dec; 11(6):611-22. PubMed ID: 20072938 [TBL] [Abstract][Full Text] [Related]
27. [Targeted therapies in digestive oncology]. Amram ML; Benamran DA; Roth AD Rev Med Suisse; 2011 May; 7(296):1131-2, 1134-6. PubMed ID: 21721202 [TBL] [Abstract][Full Text] [Related]
28. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Le Tourneau C; Vidal L; Siu LL Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176 [TBL] [Abstract][Full Text] [Related]
29. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors]. Nielsen DL; Andersson M Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954 [TBL] [Abstract][Full Text] [Related]
30. Emerging targeted therapies for breast cancer. Alvarez RH; Valero V; Hortobagyi GN J Clin Oncol; 2010 Jul; 28(20):3366-79. PubMed ID: 20530283 [TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447 [TBL] [Abstract][Full Text] [Related]
32. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Raben D; Helfrich B; Bunn PA Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632 [TBL] [Abstract][Full Text] [Related]
33. Targeted therapies in squamous cell carcinoma of the head and neck. Gold KA; Lee HY; Kim ES Cancer; 2009 Mar; 115(5):922-35. PubMed ID: 19156911 [TBL] [Abstract][Full Text] [Related]
34. Angiogenesis blockade as therapy for hepatocellular carcinoma: progress and challenges. Hao CY J Gastroenterol Hepatol; 2011 Jan; 26(1):4-6. PubMed ID: 21175786 [No Abstract] [Full Text] [Related]
35. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. El-Assal ON; Yamanoi A; Soda Y; Yamaguchi M; Igarashi M; Yamamoto A; Nabika T; Nagasue N Hepatology; 1998 Jun; 27(6):1554-62. PubMed ID: 9620326 [TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics of EGFR and VEGF inhibition. Pander J; Gelderblom H; Guchelaar HJ Drug Discov Today; 2007 Dec; 12(23-24):1054-60. PubMed ID: 18061885 [TBL] [Abstract][Full Text] [Related]
37. Emerging combination therapies to overcome resistance in EGFR-driven tumors. Ratti M; Tomasello G Anticancer Drugs; 2014 Feb; 25(2):127-39. PubMed ID: 24113593 [TBL] [Abstract][Full Text] [Related]
38. Anti-angiogenic treatment of gastrointestinal malignancies. Salmon JS; Lockhart AC; Berlin J Cancer Invest; 2005; 23(8):712-26. PubMed ID: 16377590 [TBL] [Abstract][Full Text] [Related]